Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09MRL
|
|||
| Former ID |
DNCL003490
|
|||
| Drug Name |
Pidilizumab
|
|||
| Synonyms |
CT-011
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [1], [2], [3] | |
| Company |
CureTech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [4] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7692). | |||
| REF 2 | ClinicalTrials.gov (NCT01420965) Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013 Nov 20;31(33):4199-206. | |||
| REF 4 | PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.